Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Characteristics of REM Sleep Behavior Disorder Affect the Risk of Developing an Overt Synucleinopathy
Sleep
P6 - Poster Session 6 (5:30 PM-6:30 PM)
11-005
iRBD patients are known to be at high risk for developing an overt synucleinopathy [i.e., dementia with Lewy bodies (DLB) or Parkinson’s disease (PD)] and RBD often precedes years or decades before diagnosis of DLB or PD.
To assess whether duration and/or onset age of REM sleep behavior disorder (RBD) in isolated RBD (iRBD) patients affect the outcome of evolving into an overt synucleinopathy.
Participants with polysomnography-confirmed iRBD who have been followed prospectively for >4 years were included. 
Fifteen participants (45%) developed DLB (phenoconverters) and 18 participants (55%) remained as iRBD (stable iRBD). Follow-up years did not differ between phenoconverters and stable iRBD (6.2 ± 2.5 vs 6.3 ± 1.2 years; p=0.86). Time from baseline visit to DLB diagnosis was 4.0 ± 1.9 years and time from RBD onset to DLB diagnosis was 10.9 ± 5.4 years. At baseline, phenoconverters were older (69.4 ± 6.8 vs 63.7 ± 5.6 years old; p=0.013), had lower MMSE score (27.3 ± 1.5 vs 28.9 ± 1.3; p=0.002), and had more negative DaTQUANT putamen z-scores on 123I-FP-CIT SPECT (-1.71 ± 1.42 vs -0.28 ± 1.21; p=0.004). Sex (male; 87% vs 78%; p=0.51), education years (16.7 ± 2.5 vs 17.4 ± 2.4 years; p=0.38), APOE4 carrier (27% vs 35%; p=0.60), and UPDRS part III score (3.2 ± 3.2 vs 1.5 ± 2.1; p=0.073) did not differ between the two groups. Phenoconverters presented shorter RBD duration (6.9 ± 4.4 vs 16.3 ± 12.3 years; p=0.008) and older RBD onset (62.5 ± 8.3 vs 47.3 ± 14.9 years old; p=0.001).
These findings suggest that iRBD patients with shorter duration and older onset of RBD are associated with an increased likelihood of progression into an overt synucleinopathy.
Authors/Disclosures
Toji Miyagawa, MD, PhD (Mayo Clinic)
PRESENTER
Dr. Miyagawa has nothing to disclose.
Scott Przybelski No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Timothy Lesnick No disclosure on file
Stuart McCarter, MD (Mayo Clinic) Dr. McCarter has nothing to disclose.
Erik K. St. Louis, MD (Mayo Clinic) Dr. St. Louis has received publishing royalties from a publication relating to health care. Dr. St. Louis has received publishing royalties from a publication relating to health care.
Michael Silber, MB, ChB, FAAN (Mayo Clinic) Dr. Silber has received publishing royalties from a publication relating to health care. Dr. Silber has received personal compensation in the range of $500-$4,999 for serving as a Topic writer with UpToDate.
Jonathan Graff-Radford, MD, FAAN Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Cognition therapeutics.
David T. Jones, MD (Mayo Clinic) Dr. Jones has nothing to disclose.
David S. Knopman, MD, FAAN (Mayo Clinic) Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic) Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nestle. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech, Inc.. Dr. Petersen has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche, Inc.. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.
Walter Kremers No disclosure on file
Leah K. Forsberg, PhD (Mayo Clinic) Ms. Forsberg has nothing to disclose.
Julie A. Fields, PhD (Mayo Clinic) The institution of Dr. Fields has received research support from National Institutes of Health. The institution of Dr. Fields has received research support from Patient-Centered Outcomes Research Institute.
Tanis J. Ferman (Mayo Clinic Jacksonville) Ms. Ferman has nothing to disclose.
Hugo Botha, MD (Mayo School of Graduate Medical Education, Rochester) Dr. Botha has received research support from NIH.
Vijay K. Ramanan, MD, PhD (Mayo Clinic) The institution of Dr. Ramanan has received research support from the National Institutes of Health. The institution of Dr. Ramanan has received research support from the Mangurian Foundation for Lewy Body Disease Research. The institution of Dr. Ramanan has received research support from as part of clinical trials sponsored by the Alzheimer's Association, Eisai, the Alzheimer's Treatment and Research Institute at USC, and Transposon Therapeutics, Inc.. The institution of Dr. Ramanan has received research support from Medscape. Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving as a Conference Speaker/Organizer (Honoraria) with AANI.
Laura Allen, NP (Mayo Clinic) Ms. Allen has nothing to disclose.
Kejal Kantarci, MD (Mayo Clinic) The institution of Dr. Kantarci has received research support from Eli Lilly. The institution of Dr. Kantarci has received research support from NIH. The institution of Dr. Kantarci has received research support from ADDF.
Val J. Lowe, MD (Mayo Clinic) Dr. Lowe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AVID Radiopharmaceutical. Dr. Lowe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Inc. The institution of Dr. Lowe has received research support from AVID Radiopharmaceuticals.
Bradley F. Boeve, MD, FAAN (Mayo Clinic) Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.